About Us
Biorex Diagnostics was founded 20 years ago and has become a leading manufacturer of in vitro diagnostics.
We offer accurate, reliable products across multiple product ranges including; clinical chemistry, blood grouping, immunoassay ELISA and rapid testing. Using a global distributor network, Biorex products are available to hospitals, clinics, blood banks and research facilities in over 100 countries.
We are dedicated to developing market leading products and are committed to investing in the research and development of new products and collaborating with external research facilities and universities globally.
Our Products
Biorex Diagnostics have an extensive range of IVD products available across multiple categories including key example here, key example here & key example here.
Contact us for more information about our products & services
Become a Distributor
Over the past 20 years, Biorex has built a strong network of distributors that represent us in over 100 markets. We work with distributors to deliver accurate, reliable products, customer service and are happy to assist with marketing and additional requirements to maximise the potential of each distributor in their markets.
Interested in becoming a distributor? Complete a contact form and a member of our sales team will be in touch.
Latest News
-
Biorex Diagnostics Has Rebranded
To celebrate 20 years of trading, Biorex Diagnostics have unveiled a new visual identity to reflect the growth of the business over the years. The company is constantly seeking new ways
-
What is the difference between Omicron and other COVID-19 variants?
With the new Omicron variant sweeping the world faster than any other coronavirus strain before it, how concerned should we be? On 24th November 2021, the first Omicron case was announced in
-
COVID-19 rising despite vaccine rollout
On 1st November 2021, the COVID-19 death toll surpassed five million despite the ongoing vaccine rollout, (BBC News). Although the World Health Organisation have recently released that this number could be
-
Cancer mortality rates could rise further due to the COVID-19 pandemic
The COVID-19 pandemic, specifically the initial lockdown, saw the world come to a standstill, where people in the UK were told not to leave their homes for any reason bar